Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Artificial Intelligence Enhanced ECG Screening Tool for Improving Detection of Cardiac Amyloidosis, the PREDICT-AMY Trial

Trial Status: closed to accrual

This clinical trial evaluates an artificial intelligence (AI) enabled electrocardiogram (ECG) amyloid algorithm screening tool for improving the diagnosis of cardiac amyloidosis (CA). CA is uncommon and life-threatening, but treatable. Patients with CA are commonly misdiagnosed with other heart conditions which leads to poorer outcomes. Unfortunately, since CA is uncommon, providers often overlook the diagnosis. There is no simple screening test for CA and symptoms are often vague. Since most patients have an ECG done at some point, it is ideally suited to be used to promote the diagnosis of CA. The AI-enabled ECG screening tool uses an algorithm to identify those at greatest risk for a CA diagnosis and generates a report with recommendations for follow up. The AI ECG amyloid algorithm screening tool may provide decision support for clinicians and improve the diagnosis and survival of patients with CA.